Seeking Alpha's  Instablog
Send Message is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
  • Biotech News Alert: Sunshine Biopharma (OTCQB: SBFM) Increases The Effectiveness Of Adva-27a Lead Compound 9.5-Fold Against Breast And Pancreatic Cancer In Vitro 0 comments
    Apr 7, 2014 1:10 PM | about stocks: SBFM

    Montreal, Quebec - April 7, 2014 ( Biotech Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has resolved the two isomeric forms of its lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. Sunshine Biopharma had previously announced that the concentration at which Adva-27a inhibited 50% of the activity of Topoisomerase II (IC50) was 13.7 micromolar (see press release issued on October 5, 2011). As a result of today's development Adva-27a's IC50 has dropped 9.5-fold, to 1.44 micromolar. This implies that significantly lower quantities of the drug can be used to achieve the same effect.

    "Isomeric forms of a compound refer to the fact that the compound has different arrangements of its atoms in space," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Isomeric forms do not have identical properties. In the case of Adva-27a, the molecule exists in the alpha or beta form. This is a lot like a person's left hand and right hand. While the two hands look identical, they actually are not. They are mirror images of each other but are not superimposable. The fact that they are not superimposable means that they are not identical. Similarly, the alpha and beta forms of Adva-27a are not superimposable. The implications of all of this for our future breast cancer and pancreatic cancer patients are lower therapeutic dosages, which theoretically should result in reduced side-effects."

    About Adva-27a

    Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).

    Safe Harbor Forward-Looking Statements

    To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


    Camille Sebaaly, CFO
    Sunshine Biopharma Inc.
    Direct Line: 514-814-0464

    Disclaimer/ Disclosure:The newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

    Themes: biotech, pharma Stocks: SBFM
Back To's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • Investing in Water Stocks for World Water Week being held in Stockholm, August 23 - 28, 2015. $AWR $WTR
    Aug 24, 2015
  • The Future of Money; Bitcoin & Ether Shake it up with CryptoCurrencies That Disrupt & Innovate $BITXF, $GBTC
    Jul 23, 2015
  • Colombia's Free Trade Zones are Booming:Tax rates are not the only incentives-We met with Unisys CEO ($UIS)
    Jul 21, 2015
More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.